Veru Stock Forecast, Price & News

-0.15 (-2.16 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume579,914 shs
Average Volume2.55 million shs
Market Capitalization$540.26 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

Veru logo

About Veru

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include VERU-111, an oral chemical entity that is being evaluated in open label Phase 1b and Phase 2 clinical trials in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer, as well as being evaluated in a Phase 2 clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome; and for the treatment of taxane resistant metastatic triple negative breast cancer. Its drug candidates also comprise VERU-100, a gonadotropin-releasing hormone antagonist peptide formulation to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. In addition, the company's drug candidates include Enobosarm, an oral selective androgen receptor agonist that targets the androgen receptor positive, estrogen receptor positive, and human epidermal growth factor receptor 2 metastatic breast cancer without the unwanted virilizing side effects. Further, it is advancing a new drug formulation in its specialty pharmaceutical pipeline addressing unmet medical needs in urology, such as Tadalafil and Finasteride Combination. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.92 out of 5 stars

Medical Sector

949th out of 2,218 stocks

Pharmaceutical Preparations Industry

458th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Veru (NASDAQ:VERU) Frequently Asked Questions

Is Veru a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Veru stock.
View analyst ratings for Veru
or view top-rated stocks.

What stocks does MarketBeat like better than Veru?

Wall Street analysts have given Veru a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Veru wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Veru?

Veru saw a decrease in short interest in July. As of July 15th, there was short interest totaling 1,700,000 shares, a decrease of 20.6% from the June 30th total of 2,140,000 shares. Based on an average daily volume of 1,330,000 shares, the short-interest ratio is presently 1.3 days. Approximately 2.7% of the company's stock are sold short.
View Veru's Short Interest

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Veru

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.34 million for the quarter, compared to the consensus estimate of $14.36 million. Veru had a negative trailing twelve-month return on equity of 11.24% and a negative net margin of 0.95%.
View Veru's earnings history

How has Veru's stock been impacted by Coronavirus (COVID-19)?

Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VERU stock has increased by 111.9% and is now trading at $6.78.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VERU?

5 equities research analysts have issued 1-year price targets for Veru's shares. Their forecasts range from $15.00 to $24.00. On average, they anticipate Veru's stock price to reach $19.20 in the next twelve months. This suggests a possible upside of 183.2% from the stock's current price.
View analysts' price targets for Veru
or view top-rated stocks among Wall Street analysts.

Who are Veru's key executives?

Veru's management team includes the following people:
  • Dr. Mitchell S. Steiner F.A.C.S., M.D., F.A.C.S, Chairman, Pres & CEO (Age 60, Pay $874.6k)
  • Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 62, Pay $465.02k)
  • Ms. Michele Greco, CFO & Chief Admin. Officer (Age 62, Pay $443.72k)
  • Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 53, Pay $507.01k)
  • Mr. Samuel Fisch, Director of Investor Relations
  • Mr. Michael J. Purvis, Exec. VP, Gen. Counsel & Corp. Strategy
  • Mr. Kevin J. Gilbert CPA, J.D., Exec. VP of Corp. Devel.
  • Dr. Robert H. Getzenberg, Exec. VP for Medical Affairs
  • Mr. Phillip Kuhn, Exec. VP of Strategy & Commercial
  • Dr. Domingo Rodriguez, Exec. VP of Clinical Operations (Age 59)

Who are some of Veru's key competitors?

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $6.78.

How much money does Veru make?

Veru has a market capitalization of $540.26 million and generates $42.59 million in revenue each year. The company earns $-18,970,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does Veru have?

Veru employs 339 workers across the globe.

What is Veru's official website?

The official website for Veru is

Where are Veru's headquarters?

Veru is headquartered at 48 NW 25th Street Suite 102, Miami FL, 33127.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.